CROI 2016 Program at a Glance

Program and Agenda

POSTER SESSIONS, BY CATEGORY

All poster sessions will be held in Hall A/B (poster numbers 182-756 )and Hall D (poster numbers 757-1063) from 2:45 to 4:00 PM on the scheduled day.

A. Virology P-A1 ViralTransmission andTarget Cells (Tuesday, February 23, 2016) P-A2 Viral Proteins: Regulation, Replication,Transcription (Wednesday, February 24, 2016) P-A3 Viral Proteins: Insights Into Structure (Wednesday, February 24, 2016) P-A4 Host Factors and Cell Response to Infection (Thursday, February 25, 2016) B. Molecular Epidemiology and HIV/SIV Evolution P-B1 Detection and Spread of Genetically Diverse HIV (Tuesday, February 23, 2016) P-B2 Identifying Network andTransmission Pairs (Wednesday, February 24, 2016) P-B3 Viral Genetics: Effects onTransmission, Disease, and Reinfection (Thursday, February 25, 2016) P-B4 Defining the Sequence Characteristics ofTransmittedViruses (Thursday, February 25, 2016) C. Pathogenesis: Human Studies and Animal Models P-C1 HIV and Intestinal Integrity (Tuesday, February 23, 2016) P-C2 HIV Effects on CD4+T Cells (Tuesday, February 23, 2016) P-C3 Genetics and Cell Biology of HIV Infection (Tuesday, February 23, 2016) P-C4 Immunopathogenesis (Tuesday, February 23, 2016) P-C5 HIV and Microbiomes (Wednesday, February 24, 2016) P-C6 SIV Models of Pathogenesis (Wednesday, February 24, 2016) P-C7 Immune Activation and Inflammation (Wednesday, February 24, 2016) P-C8 Pathogenesis of MucosalTransmission (Thursday, February 25, 2016) P-C9 Immune Effects of AntiretroviralTherapy (Thursday, February 25, 2016) E. Host Immune Responses to Infection, Vaccines, and Immunotherapy P-E1 Antibody Responses to HIV Infection:What DrivesThem and HowThey Affect theVirus (Tuesday, February 23, 2016) P-E2 Cellular Immunity: Change to CytotoxicT Lymphocyte and NK Cells (Tuesday, February 23, 2016) P-E3 Evaluating HIVVaccines: Preclinical to Clinical (Wednesday, February 24, 2016) P-E4 Effects of HIV on the Responses to OtherVaccines (Thursday, February 25, 2016)

F. HIV Persistence, Reservoirs, Latency, Eradication, Including Gene Therapy P-F1 Novel HIV Reservoirs (Tuesday, February 23, 2016) P-F2 HIV Reservoir: Measurement and Mechanisms of Persistence (Tuesday, February 23, 2016) P-F3 Tissue Reservoirs of HIV: Anatomic and Imaging Studies (Tuesday, February 23, 2016) P-F4 Impact of AntiretroviralTherapy onViremic Control andTissue Reservoirs (Wednesday, February 24, 2016) P-F5 Approaches to Reactivating HIV and GeneTherapy (Wednesday, February 24, 2016) P-F6 HIV Integration (Wednesday, February 24, 2016) P-F7 Stem Cells (Thursday, February 25, 2016) P-F8 HIV Persistence, Latency, and Reactivation (Thursday, February 25, 2016) G. Neuropathogenesis P-G1 Neuroimaging: Brain Structure and Functional Response (Tuesday, February 23, 2016) P-G2 Virology and Basic Neuroscience (Wednesday, February 24, 2016) P-G3 Central Nervous System: HIV Entry, Reservoirs, and Compartmentalization (Wednesday, February 24, 2016) P-G4 Host andVirus Biomarkers and Immune Response (Thursday, February 25, 2016) P-G5 Clinical Distinctions andTherapeutic Response (Thursday, February 25, 2016) H. Clinical Pharmacology P-H1 Exposure Response: Learning to Improve Safety and Efficacy (Tuesday, February 23, 2016) P-H2 Clinical Pharmacology: Pregnancy, Pediatrics, and Predictions (Wednesday, February 24, 2016) P-H3 Pharmacogenetics (Wednesday, February 24, 2016) P-H4 Pharmacokinetics in Compartments (Wednesday, February 24, 2016) P-H5 Clinical Pharmacology ofTreating Coinfections (Thursday, February 25, 2016) I. Antiretroviral Therapy: Preclinical Studies P-I1 Preclinical Studies of Activity and Resistance (Thursday, February 25, 2016) J. Antiretroviral Therapy: Randomized Clinical Trials P-J1 AntiretroviralTherapy: Randomized ClinicalTrials (Wednesday, February 24, 2016)

Poster Sessions

50

CROI 2016